Genenta is a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors.
Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro environment.
Genenta’s lead product candidate, Temferon™, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance.
Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.
News and events
Maxim Group’s 2024
Healthcare Virtual Summit
Speaker: Pierluigi Paracchi, CEO and Co-founder Genenta Science
Date: October 15-17, 2024
Where: virtual
Press Conference:
Interim Report Working Table for the Internationalisation of Biotechnology Industries
Speaker: Pierluigi Paracchi CEO Genenta Science, On. Antonio Tajani, Minister of Foreign Affairs and International Cooperation
Date: October, 16, 2024 At: 11:00 am CET
Where: Ministry of Foreign Affairs and International Cooperation, Piazzale della Farnesina 1 Rome
Supporting Materials
Save the Date / RSVP
Cross-Border Investments and Strategies in the Biotechnology Sector:
A Transatlantic Perspective
Speaker: Pierluigi Paracchi CEO Genenta Science, Michelle Rozo, NSCEB National Security Commission on Emerging Biotechnology; Mariangela Zappia, Ambassador of Italy to US; Megan Frisk, ARPA-H Advanced Research Projects Agency for Health; Mauro Battocchi, Director General for the promotion of Italy at the Italian Ministry of Foreign affairs
Date: October, 25, 2024
Where: U.S. Senate Visitors Center, Room TBA, Washington, DC 20510
Supporting Materials
Save the Date / RSVP
PIPELINE
With an initial clinical focus
on solid tumors with major unmet needs, Genenta’s platform of
autologous oncology products,
led by Temferon
in Phase 1/2a in glioblastoma,
is advancing through preclinical
and clinical assessment.
SCIENTIFIC BOARD
Our Scientists bring a unique
blend of multi-disciplinary
competence, vast experience
in cell therapy a global vision
and a commensurate
track-record in the
forefront of therapies
and drug development.
Myeloid cell-based delivery of IFN-γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses
Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens
IFNα gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment
Genenta’s Approach for Cancer Treatment